Kamada (KMDA) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kamada (KMDA) has outperformed Rezolute (RZLT) over the past year, gaining 13.7% versus a loss of 46.8%. Over five years, KMDA leads with a +47.5% price change compared with -30.2% for RZLT. Rezolute is the larger company by market cap ($448.8 million vs $448.7 million), about 1.0 times the size.
Kamada pays a dividend yielding 3.22%, while Rezolute does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KMDA | RZLT |
|---|---|---|
| Share price | $7.78 | $4.64 |
| Market cap | $448.70M | $448.79M |
| 1-day change | -1.46% | +5.94% |
| YTD return | +10.13% | +96.61% |
| 1-year return | +13.67% | -46.79% |
| 5-year return | +47.53% | -30.23% |
| P/E ratio (TTM) | 20.46 | — |
| Forward P/E | 13.48 | — |
| EPS (TTM) | $0.38 | $-0.75 |
| Dividend yield | 3.22% | 0.00% |
| Annual dividend | $0.25 | $0.00 |
| 52-week high | $9.35 | $11.46 |
| 52-week low | $6.55 | $1.07 |
| Distance from 52-week high | -16.84% | -59.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +73.63% | +111.21% |
| Average volume | 118.61K | 1.50M |
| Shares outstanding | 57.71M | 96.72M |
| Employees | 462 | 58 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KMDA has outperformed RZLT by 60.5 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
- The two companies sit in different sectors: Kamada in Health Care and Rezolute in Healthcare.
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Healthcare · Biotechnology · 58 employees
KMDA vs RZLT FAQ
Which is bigger, Kamada or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $448.79M compared with $448.70M for Kamada (KMDA).
Which stock has performed better over the past year, KMDA or RZLT?
KMDA returned +13.67% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kamada or Rezolute?
Kamada pays a dividend yielding 3.22%, while Rezolute does not currently pay a regular dividend.
Are Kamada and Rezolute in the same industry?
No. Kamada is in the Health Care sector, while Rezolute is in Healthcare.